Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com

September 2, 2022

To,
The National Stock Exchange of India Limited
Exchange Plaza, C - 1, Block – G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400051

**Kind Attn.: Mr. Binoy Yohannan, Associate Vice President, Surveillance**

**Sub: Clarification/ Confirmation on news item appearing in "Media/Publication"**

Dear Sir,

This is with reference to your email dated September 1, 2022 regarding news item which appeared in the "www.thehindubusinessline.com" dated August 30, 2022 captioned "Dr. Reddy's, Aurigene ink MoU with DNDi on neglected tropical diseases".

In this regard please note that the Company and Aurigene Pharmaceutical Services Limited (a fully owned stepdown subsidiary of the Company) and DNDi has entered into a non-binding MoU *to explore* joint opportunities to develop affordable and life-saving new drugs for Neglected Tropical Diseases.

Under this MoU parties will explore a potential collaboration to develop and market novel and improved drugs for the treatment of identified Neglected Tropical Diseases (NTDs) of national and global importance. The parties will also seek to work towards ensuring access of those drugs at affordable prices to patients in need particularly in Low and Middle-Income Countries (LMICs) that are disproportionately affected by these NTDs. This potential partnership will aim to bring DNDi's expertise in NTDs together with the scientific, technical and commercial capabilities of APSL and Dr. Reddy's – access to a pipeline of new chemical entities, pre-clinical studies, network and advocacy on these NTDs by DNDi; phase-wise clinical studies, research and development, commercial manufacturing of the Active Pharmaceutical Ingredients (API) and the finished products by APSL; distribution and commercialisation of the drugs by Dr. Reddy's.

In this connection, we would like to inform that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company makes disclosure of all events, information, etc. that have material impact on the operations/ performance of the Company which include all price sensitive information, etc., to the stock exchanges, where the Company's shares are listed.

Please note that the MoU and the exploration of potential partnership is not material, and was entered into for furtherance of Dr. Reddy's purpose of "Good Health Can't Wait". The media release was done in this regard to demonstrate our commitment to society at large.

Kindly take the above on record.

Thanking you.

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

KUMAR RANDHIR SINGH
Digitally signed by KUMAR RANDHIR SINGH
Date: 2022.09.02 12:14:03 +05'30'

K Randhir Singh
***Company Secretary & Compliance Officer***